Kalaris Therapeutics, Inc. Common Stock (KLRS) is a publicly traded Healthcare sector company. As of August 25, 2026, KLRS trades at $4.10 with a market cap of $98.79M and a P/E ratio of -8.60. KLRS moved -1.33% today. Year to date, KLRS is -51.42%; over the trailing twelve months it is +63.35%. Its 52-week range spans $2.14 to $12.90. Analyst consensus is strong buy with an average price target of $15.50. Rallies surfaces KLRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks the latest KLRS news, catalysts, market updates, source links, and AI summaries when news is available.
| Metric | Value |
|---|---|
| Price | $4.10 |
| Market Cap | $98.79M |
| P/E Ratio | -8.60 |
| EPS | $-0.48 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.90 |
| 52-Week Low | $2.14 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-11.52M |
| Gross Margin | 0.00% |
4 analysts cover KLRS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.50.